CA2850274A1 - Ecm composition, tumor microenvironment platform and methods thereof - Google Patents
Ecm composition, tumor microenvironment platform and methods thereof Download PDFInfo
- Publication number
- CA2850274A1 CA2850274A1 CA2850274A CA2850274A CA2850274A1 CA 2850274 A1 CA2850274 A1 CA 2850274A1 CA 2850274 A CA2850274 A CA 2850274A CA 2850274 A CA2850274 A CA 2850274A CA 2850274 A1 CA2850274 A1 CA 2850274A1
- Authority
- CA
- Canada
- Prior art keywords
- tumor
- response
- assay
- tissue
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3310CH2011 | 2011-10-04 | ||
| IN3310/CHE/2011 | 2011-10-04 | ||
| PCT/IB2012/055334 WO2013050962A1 (en) | 2011-10-04 | 2012-10-04 | Ecm composition, tumor microenvironment platform and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2850274A1 true CA2850274A1 (en) | 2013-04-11 |
Family
ID=54261176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850274A Abandoned CA2850274A1 (en) | 2011-10-04 | 2012-10-04 | Ecm composition, tumor microenvironment platform and methods thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US20140228246A1 (enExample) |
| EP (1) | EP2764099B1 (enExample) |
| JP (2) | JP6147259B2 (enExample) |
| AU (1) | AU2012320088C1 (enExample) |
| CA (1) | CA2850274A1 (enExample) |
| CY (1) | CY1120087T1 (enExample) |
| DK (1) | DK2764099T3 (enExample) |
| ES (1) | ES2660975T3 (enExample) |
| HU (1) | HUE036537T2 (enExample) |
| NO (1) | NO2764099T3 (enExample) |
| PT (1) | PT2764099T (enExample) |
| SG (1) | SG11201401183UA (enExample) |
| TR (1) | TR201802420T4 (enExample) |
| WO (1) | WO2013050962A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113774025A (zh) * | 2021-08-26 | 2021-12-10 | 湖南丰晖生物科技有限公司 | 一种结直肠癌顺铂耐药株的构建方法 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9810242B2 (en) | 2013-05-31 | 2017-11-07 | Eaton Corporation | Hydraulic system and method for reducing boom bounce with counter-balance protection |
| US20160287533A1 (en) * | 2013-11-27 | 2016-10-06 | Research Foundation Of The City University Of New York | Activity Enhancing Curcumin Compositions and Methods of Use |
| CN103966168B (zh) * | 2014-05-19 | 2017-05-03 | 广州恒迪生物科技有限公司 | 肿瘤活组织体外培养系统及培养方法 |
| WO2016154082A2 (en) * | 2015-03-23 | 2016-09-29 | Tang Yao | Methods of primary tissue culture and drug screening using autologous serum and fluids |
| US20180089363A1 (en) * | 2015-04-22 | 2018-03-29 | Ono Pharmaceutical Co., Ltd. | Method for extracting lead compound, method for selecting drug discovery target, device for creating scatter diagram, and data visualization method and visualization device |
| GB201507894D0 (en) * | 2015-05-08 | 2015-06-24 | Imagen Biotech Ltd | Personalised media |
| WO2017070353A1 (en) * | 2015-10-20 | 2017-04-27 | Celcuity Llc | Methods of preparing a primary cell sample |
| CN106047788A (zh) * | 2016-08-22 | 2016-10-26 | 上海逍鹏生物科技有限公司 | 一种适用于高密度细胞培养体系的培养基 |
| GB2555787A (en) * | 2016-11-07 | 2018-05-16 | Landberg Goran | Diagnostic methods |
| WO2018148336A1 (en) * | 2017-02-08 | 2018-08-16 | Mitra Rxdx, Inc. | Method of predicting clinical outcome of anticancer agents |
| WO2018185760A1 (en) | 2017-04-05 | 2018-10-11 | Yeda Research And Development Co. Ltd. | Ex-vivo culture system and methods of using same |
| IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| WO2019164951A1 (en) * | 2018-02-22 | 2019-08-29 | Mitra Rxdx, Inc. | Methods of predicting response to temporally sequenced combination therapy |
| GB201818885D0 (en) * | 2018-11-20 | 2019-01-02 | Precomb Therapeutics Ag | 3d human cancer model-based combinatiorial drug development method |
| WO2020172591A1 (en) * | 2019-02-22 | 2020-08-27 | Mitra Rxdx, Inc. | A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes |
| CA3130930A1 (en) * | 2019-03-19 | 2020-09-24 | Kyuson Yun | Methods and systems for evaluation of cell samples |
| CN112961830A (zh) * | 2021-02-25 | 2021-06-15 | 重庆医科大学附属口腔医院 | 口腔鳞癌组织脱细胞基质及其制备方法和应用 |
| CA3219233A1 (en) | 2021-06-06 | 2022-12-15 | Ravid STRAUSSMAN | Combined treatment for cancer |
| WO2023067582A1 (en) * | 2021-10-23 | 2023-04-27 | Mazumdar Shaw Medical Foundation | Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression |
| US12312631B1 (en) | 2022-06-15 | 2025-05-27 | SageMedic Corporation | High-throughput multiplexed sensitivity and resistance assay |
| PL444462A1 (pl) * | 2023-04-18 | 2024-10-21 | Uniwersytet Medyczny W Białymstoku | Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi |
| CN121320340A (zh) * | 2025-07-23 | 2026-01-13 | 广西医科大学第二附属医院(广西医科大学第二临床医学院) | 可抑制肿瘤生长的siRNA及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508188A (en) * | 1994-01-21 | 1996-04-16 | The Regents Of The University Of California | Method of growing cells in a mammal |
| FR2842822B1 (fr) * | 2002-07-26 | 2004-10-01 | Roussy Inst Gustave | Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales |
| US8071135B2 (en) * | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
| US20120213706A1 (en) * | 2009-04-15 | 2012-08-23 | University Of Medicine And Dentistry Of New Jersey | Reconstituted tumor microenvironment for anticancer drug development |
| US20130071864A1 (en) * | 2010-05-25 | 2013-03-21 | Makoto Watanabe | Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample |
-
2012
- 2012-10-04 NO NO12838648A patent/NO2764099T3/no unknown
- 2012-10-04 JP JP2014534027A patent/JP6147259B2/ja not_active Expired - Fee Related
- 2012-10-04 TR TR2018/02420T patent/TR201802420T4/tr unknown
- 2012-10-04 US US14/347,616 patent/US20140228246A1/en not_active Abandoned
- 2012-10-04 DK DK12838648.9T patent/DK2764099T3/en active
- 2012-10-04 SG SG11201401183UA patent/SG11201401183UA/en unknown
- 2012-10-04 EP EP12838648.9A patent/EP2764099B1/en not_active Not-in-force
- 2012-10-04 CA CA2850274A patent/CA2850274A1/en not_active Abandoned
- 2012-10-04 ES ES12838648.9T patent/ES2660975T3/es active Active
- 2012-10-04 PT PT128386489T patent/PT2764099T/pt unknown
- 2012-10-04 HU HUE12838648A patent/HUE036537T2/hu unknown
- 2012-10-04 AU AU2012320088A patent/AU2012320088C1/en not_active Ceased
- 2012-10-04 WO PCT/IB2012/055334 patent/WO2013050962A1/en not_active Ceased
-
2016
- 2016-09-12 JP JP2016177434A patent/JP6378273B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-21 CY CY20181100194T patent/CY1120087T1/el unknown
- 2018-10-26 US US16/172,606 patent/US20190170730A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,031 patent/US20190353640A1/en not_active Abandoned
- 2019-05-24 US US16/422,059 patent/US20190346428A1/en not_active Abandoned
- 2019-05-24 US US16/422,052 patent/US20190383796A1/en not_active Abandoned
- 2019-05-24 US US16/422,023 patent/US20190383795A1/en not_active Abandoned
- 2019-05-24 US US16/422,045 patent/US20200064333A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113774025A (zh) * | 2021-08-26 | 2021-12-10 | 湖南丰晖生物科技有限公司 | 一种结直肠癌顺铂耐药株的构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012320088A1 (en) | 2014-05-01 |
| US20190353640A1 (en) | 2019-11-21 |
| CY1120087T1 (el) | 2018-12-12 |
| EP2764099B1 (en) | 2017-11-22 |
| US20190170730A1 (en) | 2019-06-06 |
| JP6147259B2 (ja) | 2017-06-14 |
| PT2764099T (pt) | 2018-02-28 |
| EP2764099A1 (en) | 2014-08-13 |
| NO2764099T3 (enExample) | 2018-04-21 |
| JP2014534809A (ja) | 2014-12-25 |
| DK2764099T3 (en) | 2018-02-26 |
| US20190383795A1 (en) | 2019-12-19 |
| TR201802420T4 (tr) | 2018-03-21 |
| US20190383796A1 (en) | 2019-12-19 |
| JP2017061448A (ja) | 2017-03-30 |
| SG11201401183UA (en) | 2014-09-26 |
| JP6378273B2 (ja) | 2018-08-22 |
| ES2660975T3 (es) | 2018-03-26 |
| WO2013050962A1 (en) | 2013-04-11 |
| US20190346428A1 (en) | 2019-11-14 |
| US20200064333A1 (en) | 2020-02-27 |
| AU2012320088B2 (en) | 2015-07-02 |
| HUE036537T2 (hu) | 2018-07-30 |
| US20140228246A1 (en) | 2014-08-14 |
| EP2764099A4 (en) | 2015-05-06 |
| AU2012320088B9 (en) | 2015-07-16 |
| AU2012320088C1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012320088B2 (en) | ECM composition, tumor microenvironment platform and methods thereof | |
| JP6912538B2 (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| US10053692B2 (en) | Methods relating to circulating tumor cell clusters and the treatment of cancer | |
| Lin et al. | RETRACTED ARTICLE: MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1 | |
| Huang et al. | Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness | |
| Zhou et al. | GPRC5A promotes lung colonization of esophageal squamous cell carcinoma | |
| WO2019057919A1 (en) | METHODS AND KITS FOR THE PROGNOSIS OF LUNG ADENOCARCINOMA | |
| CN111886499B (zh) | 基于检测肿瘤细胞中rad51焦点的方法 | |
| Zhu et al. | Heterogeneous distribution pattern of CD3+ tumor-infiltrated lymphocytes (TILs) and high combined positive score (CPS) favored the prognosis of resected early stage small-cell lung cancer | |
| WO2019057913A1 (en) | METHOD AND KITS FOR THE PROGNOSIS OF SQUAMOUS CARCINOMA PULMONARY (SCC) | |
| Chiappori et al. | Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer | |
| Charpin et al. | Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas | |
| Zhai et al. | The relationship between the expressions of tumor associated fibroblasts Cav-1 and MCT4 and the prognosis of papillary carcinoma of breast. | |
| Cros et al. | Predictive value of metabolic state on PanNET response to mTOR inhibitors | |
| McCarthy | Study of the roles of autophagy in human follicular and diffuse large B-cell lymphoma | |
| Teng et al. | Elucidating the Correlation between Leupaxin as a Prognostic Biomarker and Immunotherapeutic Efficacy in Esophageal Squamous Cell Carcinoma | |
| Di Claudio | Endometriosis: involvement of stem cells and clinical impact | |
| Zeng | Disruption of NFκB Driven Breast Cancer–Bone Cell Crosstalk by TRAF Inhibition | |
| Daver et al. | The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140327 |
|
| FZDE | Discontinued |
Effective date: 20210901 |